New drug combo tested in fight against advanced pancreatic cancer
NCT ID NCT06059001
Summary
This early-stage study is testing the safety and initial effects of an experimental drug called OMO-103 when given alongside standard chemotherapy (gemcitabine/nab-paclitaxel) to patients with newly diagnosed metastatic pancreatic cancer. The main goal is to find a safe dose and see how well the body handles the combination. Researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Gregorio Marañon
Madrid, Madrid, 28007, Spain
-
Hospital Miguel Servet
Zaragoza, Zaragoza, 5009, Spain
-
Hospital Regional Universitario de Málaga
Málaga, Spain, 29010, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Vall d´Hebrón
Barcelona, Barcelona, 08035, Spain
-
ICO Hopsitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Conditions
Explore the condition pages connected to this study.